WASHINGTON (Reuters) - Hormone replacement therapy can raise the risk of an uncommon type of breast cancer fourfold after just three years, U.S. researchers reported on Monday. They found women who took combined estrogen/progestin hormone-replacement therapy for three years or more had four times the usual risk of lobular breast cancer.
